

Elena A Govorkova

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1948838/elena-a-govorkova-publications-by-citations.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

108
papers

6,468
citations

44
h-index

79
g-index

115
ext. papers

7,085
ext. citations

7.8
avg, IF

5.62
L-index

#	Paper	IF	Citations
108	H5N1 influenza--continuing evolution and spread. <i>New England Journal of Medicine</i> , 2006 , 355, 2174-7	59.2	302
107	The polymerase complex genes contribute to the high virulence of the human H5N1 influenza virus isolate A/Vietnam/1203/04. <i>Journal of Experimental Medicine</i> , 2006 , 203, 689-97	16.6	291
106	Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. <i>Journal of Virology</i> , 2005 , 79, 2191-8	6.6	285
105	T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. <i>Journal of Virology</i> , 2013 , 87, 3741-51	6.6	247
104	Continuing challenges in influenza. <i>Annals of the New York Academy of Sciences</i> , 2014 , 1323, 115-39	6.5	215
103	Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. <i>Antimicrobial Agents and Chemotherapy</i> , 2005 , 49, 4075-84	5.9	210
102	Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. <i>Antimicrobial Agents and Chemotherapy</i> , 2001 , 45, 2723-32	5.9	195
101	Influenza: emergence and control. <i>Journal of Virology</i> , 2004 , 78, 8951-9	6.6	178
100	Structure of antigenic sites on the haemagglutinin molecule of H5 avian influenza virus and phenotypic variation of escape mutants. <i>Journal of General Virology</i> , 2002 , 83, 2497-2505	4.9	163
99	Epitope mapping of the hemagglutinin molecule of a highly pathogenic H5N1 influenza virus by using monoclonal antibodies. <i>Journal of Virology</i> , 2007 , 81, 12911-7	6.6	153
98	Characterization of H5N1 influenza viruses that continue to circulate in geese in southeastern China. <i>Journal of Virology</i> , 2002 , 76, 118-26	6.6	150
97	Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. <i>Journal of Virology</i> , 2007 , 81, 12418-26	6.6	149
96	Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. <i>Antiviral Research</i> , 2006 , 70, 121-31	10.8	148
95	Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. <i>Journal of Virology</i> , 2006 , 80, 8787-95	6.6	145
94	Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. <i>Journal of Infectious Diseases</i> , 2005 , 192, 665-72 ⁷		141
93	The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. <i>Antiviral Research</i> , 2000 , 48, 101-15	10.8	133
92	Inefficient transmission of H5N1 influenza viruses in a ferret contact model. <i>Journal of Virology</i> , 2007 , 81, 6890-8	6.6	130

91	Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 1414-24	5.9	128
90	Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. <i>Journal of Infectious Diseases</i> , 2006 , 194, 159-67	7	121
89	Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 4855-63	5.9	112
88	Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 3889-97	5.9	107
87	Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 12915-20	11.5	106
86	The pH of activation of the hemagglutinin protein regulates H5N1 influenza virus pathogenicity and transmissibility in ducks. <i>Journal of Virology</i> , 2010 , 84, 1527-35	6.6	104
85	Drugs in development for influenza. <i>Drugs</i> , 2010 , 70, 1349-62	12.1	101
84	Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance. <i>Antiviral Research</i> , 2013 , 100, 520-34	10.8	95
83	Detection of amantadine-resistant variants among avian influenza viruses isolated in North America and Asia. <i>Virology</i> , 2005 , 341, 102-6	3.6	93
82	Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued monitoring. <i>Antiviral Research</i> , 2013 , 98, 297-304	10.8	88
81	Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets. <i>PLoS Pathogens</i> , 2010 , 6, e1001022	7.6	85
80	Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People's Democratic Republic. <i>Journal of General Virology</i> , 2010 , 91, 949-54	4.9	82
79	Amantadine-Oseltamivir Combination therapy for H5N1 Influenza Virus Infection in Mice. <i>Antiviral Therapy</i> , 2007 , 12, 363-370	1.6	79
78	Mammalian adaptation of influenza A(H7N9) virus is limited by a narrow genetic bottleneck. <i>Nature Communications</i> , 2015 , 6, 6553	17.4	70
77	Impaired wound healing predisposes obese mice to severe influenza virus infection. <i>Journal of Infectious Diseases</i> , 2012 , 205, 252-61	7	70
76	Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets. <i>PLoS Pathogens</i> , 2010 , 6, e1000933	7.6	68
75	Efficacy of H5 influenza vaccines produced by reverse genetics in a lethal mouse model. <i>Journal of Infectious Diseases</i> , 2005 , 191, 1216-20	7	65
74	Pathogenicity and vaccine efficacy of different clades of Asian H5N1 avian influenza A viruses in domestic ducks. <i>Journal of Virology</i> , 2008 , 82, 11374-82	6.6	64

73	Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. <i>Antiviral Therapy</i> , 2007 , 12, 363-70	1.6	60
72	Generation of high-yielding influenza A viruses in African green monkey kidney (Vero) cells by reverse genetics. <i>Journal of Virology</i> , 2004 , 78, 1851-7	6.6	58
71	Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancer. <i>Pediatric Infectious Disease Journal</i> , 2011 , 30, 284-8	3.4	56
70	Combination chemotherapy for influenza. <i>Viruses</i> , 2010 , 2, 1510-29	6.2	54
69	The epidemiological and molecular aspects of influenza H5N1 viruses at the human-animal interface in Egypt. <i>PLoS ONE</i> , 2011 , 6, e17730	3.7	49
68	Novel Highly Pathogenic Avian A(H5N2) and A(H5N8) Influenza Viruses of Clade 2.3.4.4 from North America Have Limited Capacity for Replication and Transmission in Mammals. <i>MSphere</i> , 2016 , 1,	5	47
67	Oseltamivir prophylactic regimens prevent H5N1 influenza morbidity and mortality in a ferret model. <i>Journal of Infectious Diseases</i> , 2008 , 197, 1315-23	7	45
66	Contribution of H7 haemagglutinin to amantadine resistance and infectivity of influenza virus. <i>Journal of General Virology</i> , 2007 , 88, 1266-1274	4.9	44
65	Risk assessment of H2N2 influenza viruses from the avian reservoir. <i>Journal of Virology</i> , 2014 , 88, 1175-886	3.6	42
64	Continuing threat of influenza (H5N1) virus circulation in Egypt. <i>Emerging Infectious Diseases</i> , 2011 , 17, 2306-8	10.2	42
63	Epistatic interactions between neuraminidase mutations facilitated the emergence of the oseltamivir-resistant H1N1 influenza viruses. <i>Nature Communications</i> , 2014 , 5, 5029	17.4	40
62	Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 3088-96	5.9	40
61	Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice. <i>Antiviral Research</i> , 2008 , 80, 150-7	10.8	40
60	Human-like receptor specificity does not affect the neuraminidase-inhibitor susceptibility of H5N1 influenza viruses. <i>PLoS Pathogens</i> , 2008 , 4, e1000043	7.6	40
59	The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute Respiratory Distress Syndrome. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 2118-31	5.9	38
58	Combinations of Oseltamivir and T-705 Extend the Treatment Window for Highly Pathogenic Influenza A(H5N1) Virus Infection in Mice. <i>Scientific Reports</i> , 2016 , 6, 26742	4.9	38
57	Virulence and transmissibility of H1N2 influenza virus in ferrets imply the continuing threat of triple-reassortant swine viruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 15900-5	11.5	37
56	Determination of neuraminidase kinetic constants using whole influenza virus preparations and correction for spectroscopic interference by a fluorogenic substrate. <i>PLoS ONE</i> , 2013 , 8, e71401	3.7	37

55	Fitness costs for Influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 2718-30	5.9	36
54	What is the optimal therapy for patients with H5N1 influenza?. <i>PLoS Medicine</i> , 2009 , 6, e1000091	11.6	36
53	Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets. <i>Vaccine</i> , 2009 , 27, 4187-95	4.1	35
52	A Novel Endonuclease Inhibitor Exhibits Broad-Spectrum Anti-Influenza Virus Activity In Vitro. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 5504-14	5.9	34
51	Unique Determinants of Neuraminidase Inhibitor Resistance among N3, N7, and N9 Avian Influenza Viruses. <i>Journal of Virology</i> , 2015 , 89, 10891-900	6.6	33
50	Novel roles of focal adhesion kinase in cytoplasmic entry and replication of influenza A viruses. <i>Journal of Virology</i> , 2014 , 88, 6714-28	6.6	33
49	Identification of the I38T PA Substitution as a Resistance Marker for Next-Generation Influenza Virus Endonuclease Inhibitors. <i>MBio</i> , 2018 , 9,	7.8	32
48	Competitive fitness of oseltamivir-sensitive and -resistant highly pathogenic H5N1 influenza viruses in a ferret model. <i>Journal of Virology</i> , 2010 , 84, 8042-50	6.6	32
47	The neuraminidase inhibitor oseltamivir is effective against A/Anhui/1/2013 (H7N9) influenza virus in a mouse model of acute respiratory distress syndrome. <i>Journal of Infectious Diseases</i> , 2014 , 209, 1343-53	7.53	30
46	Assessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferrets. <i>Antiviral Research</i> , 2011 , 91, 81-8	10.8	30
45	Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype. <i>Journal of Virology</i> , 2010 , 84, 9800-9	6.6	30
44	Screening for Neuraminidase Inhibitor Resistance Markers among Avian Influenza Viruses of the N4, N5, N6, and N8 Neuraminidase Subtypes. <i>Journal of Virology</i> , 2018 , 92,	6.6	28
43	Prevention of influenza by targeting host receptors using engineered proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 6401-6	11.5	25
42	Fitness of neuraminidase inhibitor-resistant influenza A viruses. <i>Current Opinion in Virology</i> , 2011 , 1, 574-81	7.81	24
41	Influenza A and B viruses with reduced baloxavir susceptibility display attenuated in vitro fitness but retain ferret transmissibility. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 8593-8601	11.5	23
40	Consequences of resistance: in vitro fitness, in vivo infectivity, and transmissibility of oseltamivir-resistant influenza A viruses. <i>Influenza and Other Respiratory Viruses</i> , 2013 , 7 Suppl 1, 50-7	5.6	23
39	Therapeutics against influenza. <i>Current Topics in Microbiology and Immunology</i> , 2013 , 370, 273-300	3.3	20
38	Competitive fitness of influenza B viruses with neuraminidase inhibitor-resistant substitutions in a coinfection model of the human airway epithelium. <i>Journal of Virology</i> , 2015 , 89, 4575-87	6.6	18

37	Gain-of-function experiments on H7N9. <i>Science</i> , 2013 , 341, 612-3	33.3	18
36	Novel genotyping and quantitative analysis of neuraminidase inhibitor resistance-associated mutations in influenza A viruses by single-nucleotide polymorphism analysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 4718-27	5.9	18
35	Influenza H5 virus escape mutants: immune protection and antibody production in mice. <i>Virus Research</i> , 2004 , 99, 205-8	6.4	15
34	Characterizing Emerging Canine H3 Influenza Viruses. <i>PLoS Pathogens</i> , 2020 , 16, e1008409	7.6	15
33	Influenza A viruses of swine circulating in the United States during 2009-2014 are susceptible to neuraminidase inhibitors but show lineage-dependent resistance to adamantanes. <i>Antiviral Research</i> , 2015 , 117, 10-9	10.8	13
32	Influenza A (H15N4) virus isolation in Western Siberia, Russia. <i>Journal of Virology</i> , 2013 , 87, 3578-82	6.6	11
31	Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection. <i>Scientific Reports</i> , 2017 , 7, 7345	4.9	11
30	A pharmacologically immunosuppressed mouse model for assessing influenza B virus pathogenicity and oseltamivir treatment. <i>Antiviral Research</i> , 2017 , 148, 20-31	10.8	11
29	Drug Repurposing Identifies Inhibitors of Oseltamivir-Resistant Influenza Viruses. <i>Angewandte Chemie - International Edition</i> , 2016 , 55, 3438-41	16.4	10
28	Susceptibility of avian influenza viruses of the N6 subtype to the neuraminidase inhibitor oseltamivir. <i>Antiviral Research</i> , 2012 , 93, 322-9	10.8	10
27	The PA Endonuclease Inhibitor RO-7 Protects Mice from Lethal Challenge with Influenza A or B Viruses. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	9
26	Competitive Fitness of Influenza B Viruses Possessing E119A and H274Y Neuraminidase Inhibitor Resistance-Associated Substitutions in Ferrets. <i>PLoS ONE</i> , 2016 , 11, e0159847	3.7	9
25	Sialic acid-binding protein Sp2CBMTD protects mice against lethal challenge with emerging influenza A (H7N9) virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 1495-504	5.9	8
24	Oseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study Design. <i>PLoS ONE</i> , 2015 , 10, e0138069	3.7	7
23	An I436N substitution confers resistance of influenza A(H1N1)pdm09 viruses to multiple neuraminidase inhibitors without affecting viral fitness. <i>Journal of General Virology</i> , 2018 , 99, 292-302	4.9	7
22	Competitive transmissibility and fitness of oseltamivir-sensitive and resistant pandemic influenza H1N1 viruses in ferrets. <i>Influenza and Other Respiratory Viruses</i> , 2011 , 5, 79-82	5.6	7
21	Neuraminidase inhibitor susceptibility and neuraminidase enzyme kinetics of human influenza A and B viruses circulating in Thailand in 2010-2015. <i>PLoS ONE</i> , 2018 , 13, e0190877	3.7	6
20	Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isrv Antiviral group. <i>Antiviral Research</i> , 2021 , 194, 105158	10.8	5

19	Non-rigid Diarylmethyl Analogs of Baloxavir as Cap-Dependent Endonuclease Inhibitors of Influenza Viruses. <i>Journal of Medicinal Chemistry</i> , 2020 , 63, 9403-9420	8.3	4
18	A Novel Neuraminidase-Dependent Hemagglutinin Cleavage Mechanism Enables the Systemic Spread of an H7N6 Avian Influenza Virus. <i>MBio</i> , 2019 , 10,	7.8	4
17	Optimizing T-705 (favipiravir) treatment of severe influenza B virus infection in the immunocompromised mouse model. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 1333-1341	5.1	3
16	Lethality to Ferrets of H5N1 Influenza Viruses Isolated from Humans and Poultry in 2004. <i>Journal of Virology</i> , 2006 , 80, 6195-6195	6.6	3
15	Profiling of Laninamivir-Resistant Substitutions in N3 to N9 Avian Influenza Virus Neuraminidase Subtypes and Their Association with Susceptibility. <i>Journal of Virology</i> , 2020 , 95,	6.6	3
14	Multiple polymerase acidic (PA) I38X substitutions in influenza A(H1N1)pdm09 virus permit polymerase activity and cause reduced baloxavir inhibition. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 957-960	5.1	2
13	Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018-2020.. <i>Antiviral Research</i> , 2022 , 200, 105281	10.8	2
12	Drug Repurposing Identifies Inhibitors of Oseltamivir-Resistant Influenza Viruses. <i>Angewandte Chemie</i> , 2016 , 128, 3499-3502	3.6	1
11	Synthesis, inhibitory activity and oral dosing formulation of AV5124, the structural analogue of influenza virus endonuclease inhibitor baloxavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 1010-1018	5.1	1
10	Influenza B viruses from different genetic backgrounds are variably impaired by neuraminidase inhibitor resistance-associated substitutions. <i>Antiviral Research</i> , 2020 , 173, 104669	10.8	1
9	Monoclonal Antibody Therapy Protects Pharmacologically Immunosuppressed Mice from Lethal Infection with Influenza B Virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	1
8	Baloxavir Treatment Delays Influenza B Virus Transmission in Ferrets and Results in Limited Generation of Drug-Resistant Variants. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65, e0113721	5.9	1
7	Cross-protection studies with H5 influenza viruses. <i>International Congress Series</i> , 2001 , 1219, 767-773		
6	Characterizing Emerging Canine H3 Influenza Viruses 2020 , 16, e1008409		
5	Characterizing Emerging Canine H3 Influenza Viruses 2020 , 16, e1008409		
4	Characterizing Emerging Canine H3 Influenza Viruses 2020 , 16, e1008409		
3	Characterizing Emerging Canine H3 Influenza Viruses 2020 , 16, e1008409		
2	Characterizing Emerging Canine H3 Influenza Viruses 2020 , 16, e1008409		

1 Characterizing Emerging Canine H3 Influenza Viruses **2020**, 16, e1008409